| Angion Biomedica is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics to address chronic and progressive fibrotic diseases. Co.'s product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases. ANG-3070 has demonstrated activity as an anti-fibrotic agent in a variety of animal models. Co. is also continuing to develop its preclinical programs. Co.'s ROCK2 program, which is targeted towards the treatment of fibrotic diseases and CYP11B2 program, which is targeted towards diseases related to aldosterone synthase dysregulation. We show 8 historical shares outstanding datapoints in our ANGN shares outstanding history coverage, used to compute ANGN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANGN market cap history over the course of time is important for investors
interested in comparing ANGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANGN versus a peer is one thing; comparing
ANGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANGN can fluctuate over the course of history.
With this page we aim to empower investors researching ANGN by allowing them to research the ANGN market cap history.